Thymidine → Deoxyuridine
반응식
[C@@H:1]1([N:9]2[CH:17]=[C:15](C)[C:13](=[O:14])[NH:12][C:10]2=[O:11])[O:8][C@H:5]([CH2:6][OH:7])[C@@H:3]([OH:4])[CH2:2]1.CC1C(=O)NC(=O)N([C@@H]2O[C@H](COP(O)(O)=O)[C@@H](O)C2)C=1>>[C@@H:1]1([N:9]2[CH:17]=[CH:15][C:13](=[O:14])[NH:12][C:10]2=[O:11])[O:8][C@H:5]([CH2:6][OH:7])[C@@H:3]([OH:4])[CH2:2]1참가 물질
3
실험 절차
Strain CMG1115 (see Table 4 above) can be modified to a genotype additionally including tdk+ (thymidine kinase) and thyA- (thymidylate synthase negative) in order to produce deoxyuridine in accordance with the present invention. Such a modified strain derived from strain CMG1115 (containing pCG144), is streaked on LB agar plates with 100 ug/mL ampicillin and 50 mg/ml thymidine and grown at 30° C. Single colonies are picked into 25 mL of LB broth with 100 μg/ml ampicillin in a 250 mL baffle flask and incubated at 30° C. for 8 hours. This culture (0.5 mL) is then used to seed flasks with production media with the composition presented in Table 11.
출처 및 근거
- ORD 기록
- ord-d07cdb871cce4809a8eaeb9c7358a3b4
- 출처 데이터셋
- uspto-grants-1993_05